Developer docs
API playgroundTry for free, no card

Search company profiles

Pharsight

Full company profile

uuid0008szm

Namestring
Pharsight
Legal namestring
Certara USA, Inc.
Websiteurl
pharsight.com
Company typeenum
Public
Founded yearint
1998
Descriptiontext

Pharsight Corporation is a privately held software and scientific consulting services provider headquartered in Mountain View, California, founded in 1995. The firm employs 51-100 people and operates in the United States, serving pharmaceutical and biotechnology companies, per its published firmographic description. Pharsight was acquired by Certara in 2012, and the consolidated dataset suggests Pharsight's legacy clinical trial simulation and pharmacokinetic/pharmacodynamic expertise has been folded into Certara's broader drug development portfolio spanning biosimulation, regulatory submissions, and scientific informatics.

The input does not surface Pharsight's current product roadmap, customer roster, pricing structure, or revenue mechanics as a standalone entity. Certara (NASDAQ: CERT), the acquirer, has scaled into a 1,550+ employee operation across 30+ countries with an integrated software and services platform (Phoenix, Simcyp, Pinnacle 21, D360, GlobalSubmit, BaseCase, CoAuthor, Certara.AI), enterprise subscription pricing, and recognition as a contributor to 90% of FDA novel drug approvals from 2014-2025. That operating and financial scale reflects the parent, not Pharsight as currently constituted.

As a result, the standalone Pharsight entity appears positioned as a specialist services firm serving US pharma/biotech, with limited public visibility into its current market position, customer concentration, or expansion cadence. Investment-grade judgments on Pharsight's standalone scale, moat depth, and trajectory are constrained by the data gap and rely primarily on its firmographic fingerprint.

Short descriptiontext

Pharsight Corporation is a private US software and scientific consulting services firm founded in 1995, headquartered in Mountain View, California, serving pharmaceutical and biotechnology clients with 51-100 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial simulation, pharmacokinetic analysis, pharmacodynamic modeling, drug development software, scientific consulting services
Industry4 codes
PRIMARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAOAN
Market Access, Pricing & Reimbursement (Evidence Generation) FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Software Publishers513210
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Management Consulting Services8742
Product category
Drug Development Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software Licenses and Subscriptions
TypeSubscription Recurring
Description

Enterprise software solutions including Phoenix, Pinnacle 21, Simcyp, D360, GlobalSubmit, BaseCase, Certara.AI, CoAuthor, Chemaxon, and SEND Explorer offered through licensing and subscription models

certara.com
2Professional Services
TypeProfessional Services
Description

Modeling and simulation services, biometrics and data science, drug development support, regulatory strategy, real-world evidence and market access, and therapeutic specialty consulting services

certara.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise B2B pricing for pharma, biotech, and CRO customers
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based / Not publicly disclosed - enterprise licensing and services tailored to customer requirements

certara.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 12 records shown
1Phoenix
Description

PK, PD, and toxicokinetic analysis and modeling software

certara.com
+11 more records
Core offering1 text field

Pharsight Corporation provides software and scientific consulting services to pharmaceutical and biotechnology companies. Its portfolio centers on clinical trial simulation and pharmacokinetic/pharmacodynamic (PK/PD) analysis tools used by drug development teams to model drug behavior, optimize dosing, and support go/no-go decisions during preclinical and clinical phases. Pharsight was acquired by Certara in 2012, and its flagship Phoenix platform is now part of Certara's broader drug development software suite.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% of all novel drug approvals by FDA from 2014 through 2025 involved Certara customers
+4 more records
Product overview1 text field

Certara offers a comprehensive drug development solutions platform comprising multiple integrated software products spanning the entire drug development lifecycle from discovery through market access. The portfolio includes Phoenix for PK/PD/toxicokinetic modeling, Pinnacle 21 for regulatory data standardization, Certara IQ for quantitative systems pharmacology, Simcyp for PBPK simulation, D360 for scientific informatics, GlobalSubmit for eCTD submissions, BaseCase for value storytelling, SEND Explorer for nonclinical data visualization, Certara.AI as the AI platform for life sciences, and CoAuthor for generative AI-powered regulatory writing. These products are complemented by strategic services including regulatory strategy, modeling and simulation, biometrics and data science, drug development support, and therapeutic area expertise. The platform serves biotech, pharma, and CRO customers with solutions aligned with recognized industry standards and regulatory requirements.

Product and service2 records
1Phoenix
CategoryPharmacokinetic/Pharmacodynamic Modeling Software
Description

PK, PD, and toxicokinetic analysis and modeling platform originally developed by Pharsight for pharmacokinetic/pharmacodynamic studies used by drug development teams at pharmaceutical and biotechnology companies.

2Scientific Consulting Services
CategoryScientific Consulting
Description

Expert scientific consulting supporting clinical trial simulation, pharmacokinetic/pharmacodynamic analysis, and drug development strategy for pharmaceutical and biotechnology clients.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Certara was reappointed for a European Medicines Agency contract, expanding opportunities to shape the future of real-world evidence for regulatory decision-making. This partnership positions Certara as a key contributor to EMA regulatory science initiatives.

Strategic tierCoreTypeTechnology or Integration
Description

Certara integrated D360 with Secondary Intelligence software to enhance predicting drug safety risk. This integration combines D360's scientific informatics with Secondary Intelligence's safety analysis capabilities.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

Veeva is a direct peer in life-sciences cloud software, offering Vault-based solutions that overlap with Certara's regulatory (eCTD), clinical, and quality software. Both sell enterprise subscription software to large pharma and biotech.

TypeDirect peer
Description

Simulations Plus directly competes with Certara's Simcyp and Phoenix through its GastroPlus, MonolixSuite and other PBPK/PKPD modeling tools, serving the same model-informed drug development buyers.

TypeDirect peer
Description

Schrödinger competes with Certara in computational drug discovery and predictive modeling, offering physics-based and ML platforms used by similar pharma and biotech R&D customers.

TypeBroad incumbent
Description

IQVIA is a broad incumbent spanning clinical research services, real-world evidence and technology platforms (e.g., EDC, CTMS) that overlap with Certara's clinical, regulatory and real-world evidence offerings to large pharma.

TypeBroad incumbent
Description

ICON is a global CRO with growing technology-enabled services in biometrics, regulatory and clinical trial delivery, competing with Certara's services arm for pharma and biotech outsourcing budgets.

TypeBroad incumbent
Description

Medidata provides the Rave EDC/CTMS/eCOA platform used widely in clinical trials, making it a broad incumbent adjacent to Certara's trial-related modeling and Pinnacle 21 CDISC compliance tooling.

TypeBroad incumbent
Description

Charles River provides preclinical CRO services and scientific software-supported workflows that overlap with Certara's preclinical modeling and consulting offerings to pharma and biotech.

TypeBroad incumbent
Description

Labcorp's early development and clinical trial services compete with Certara's services arm for pharma R&D outsourcing, particularly in clinical pharmacology and bioanalytical work.

TypeEmerging player
Description

L7 Informatics offers a scientific data and workflow platform for life sciences R&D, an emerging alternative to Certara's D360 scientific informatics offering.

TypeEmerging player
Description

ArisGlobal provides life-sciences R&D technology including pharmacovigilance and regulatory platforms, overlapping with Certara's drug safety, regulatory submission and pharmacovigilance services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharsight

Drug Development Softwarepharsight.com

Pharsight Corporation is a private US software and scientific consulting services firm founded in 1995, headquartered in Mountain View, California, serving pharmaceutical and biotechnology clients with 51-100 employees.

What Pharsight does

Pharsight Corporation is a privately held software and scientific consulting services provider headquartered in Mountain View, California, founded in 1995. The firm employs 51-100 people and operates in the United States, serving pharmaceutical and biotechnology companies, per its published firmographic description. Pharsight was acquired by Certara in 2012, and the consolidated dataset suggests Pharsight's legacy clinical trial simulation and pharmacokinetic/pharmacodynamic expertise has been folded into Certara's broader drug development portfolio spanning biosimulation, regulatory submissions, and scientific informatics.

The input does not surface Pharsight's current product roadmap, customer roster, pricing structure, or revenue mechanics as a standalone entity. Certara (NASDAQ: CERT), the acquirer, has scaled into a 1,550+ employee operation across 30+ countries with an integrated software and services platform (Phoenix, Simcyp, Pinnacle 21, D360, GlobalSubmit, BaseCase, CoAuthor, Certara.AI), enterprise subscription pricing, and recognition as a contributor to 90% of FDA novel drug approvals from 2014-2025. That operating and financial scale reflects the parent, not Pharsight as currently constituted.

As a result, the standalone Pharsight entity appears positioned as a specialist services firm serving US pharma/biotech, with limited public visibility into its current market position, customer concentration, or expansion cadence. Investment-grade judgments on Pharsight's standalone scale, moat depth, and trajectory are constrained by the data gap and rely primarily on its firmographic fingerprint.

Pharsight firmographics

Firmographics
Name
Pharsight
Legal name
Certara USA, Inc.
Website
https://pharsight.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Short description
Pharsight Corporation is a private US software and scientific consulting services firm founded in 1995, headquartered in Mountain View, California, serving pharmaceutical and biotechnology clients with 51-100 employees.
Ownership category
akta.pro rank

Pharsight industry classification

Industry
Product category
Drug Development Software
NAICS
Software Publishers (513210), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Prepackaged Software (7372), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAOAN
Market Access, Pricing & Reimbursement (Evidence Generation) FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Clinical trial simulation
  • Pharmacokinetic analysis
  • Pharmacodynamic modeling
  • Drug development software
  • Scientific consulting services

Where Pharsight is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pharsight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software Licenses and Subscriptions: Enterprise software solutions including Phoenix, Pinnacle 21, Simcyp, D360, GlobalSubmit, BaseCase, Certara.AI, CoAuthor, Chemaxon, and SEND Explorer offered through licensing and subscription models
  2. Professional Services: Modeling and simulation services, biometrics and data science, drug development support, regulatory strategy, real-world evidence and market access, and therapeutic specialty consulting services

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise B2B pricing for pharma, biotech, and CRO customers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Pharsight product offering

Product offering

Core offering

Pharsight Corporation provides software and scientific consulting services to pharmaceutical and biotechnology companies. Its portfolio centers on clinical trial simulation and pharmacokinetic/pharmacodynamic (PK/PD) analysis tools used by drug development teams to model drug behavior, optimize dosing, and support go/no-go decisions during preclinical and clinical phases. Pharsight was acquired by Certara in 2012, and its flagship Phoenix platform is now part of Certara's broader drug development software suite.

Product overview

Certara offers a comprehensive drug development solutions platform comprising multiple integrated software products spanning the entire drug development lifecycle from discovery through market access. The portfolio includes Phoenix for PK/PD/toxicokinetic modeling, Pinnacle 21 for regulatory data standardization, Certara IQ for quantitative systems pharmacology, Simcyp for PBPK simulation, D360 for scientific informatics, GlobalSubmit for eCTD submissions, BaseCase for value storytelling, SEND Explorer for nonclinical data visualization, Certara.AI as the AI platform for life sciences, and CoAuthor for generative AI-powered regulatory writing. These products are complemented by strategic services including regulatory strategy, modeling and simulation, biometrics and data science, drug development support, and therapeutic area expertise. The platform serves biotech, pharma, and CRO customers with solutions aligned with recognized industry standards and regulatory requirements.

Differentiator

Problem solved

Functional benefit

Brands

  • Phoenix: PK, PD, and toxicokinetic analysis and modeling software
  • Pinnacle 21
  • Simcyp
  • D360
  • GlobalSubmit
  • Certara.AI
  • CoAuthor
  • BaseCase
  • SEND Explorer
  • Non-Animal Navigator
  • Certara IQ
  • Chemaxon

Products and services

  • Phoenix PK, PD, and toxicokinetic analysis and modeling platform originally developed by Pharsight for pharmacokinetic/pharmacodynamic studies used by drug development teams at pharmaceutical and biotechnology companies.
  • Scientific Consulting Services Expert scientific consulting supporting clinical trial simulation, pharmacokinetic/pharmacodynamic analysis, and drug development strategy for pharmaceutical and biotechnology clients.

Quantifiable outcome

  • 90% of all novel drug approvals by FDA from 2014 through 2025 involved Certara customers
  • +4 more outcomes

Companies that use Pharsight

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Pharsight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature11 records

Pharsight partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • European Medicines Agency (EMA)coreStrategic or Co-development PartnerCertara was reappointed for a European Medicines Agency contract, expanding opportunities to shape the future of real-world evidence for regulatory decision-making. This partnership positions Certara as a key contributor to EMA regulatory science initiatives.
  • Secondary IntelligencecoreTechnology or IntegrationCertara integrated D360 with Secondary Intelligence software to enhance predicting drug safety risk. This integration combines D360's scientific informatics with Secondary Intelligence's safety analysis capabilities.

Scale indicators8 records

Recent moves1 record

Pharsight competitors and assessment

Company assessment

Direct peers

  • Veeva Systems: Veeva is a direct peer in life-sciences cloud software, offering Vault-based solutions that overlap with Certara's regulatory (eCTD), clinical, and quality software. Both sell enterprise subscription software to large pharma and biotech.
  • Simulations Plus: Simulations Plus directly competes with Certara's Simcyp and Phoenix through its GastroPlus, MonolixSuite and other PBPK/PKPD modeling tools, serving the same model-informed drug development buyers.
  • Schrödinger: Schrödinger competes with Certara in computational drug discovery and predictive modeling, offering physics-based and ML platforms used by similar pharma and biotech R&D customers.

Broad incumbents

  • IQVIA: IQVIA is a broad incumbent spanning clinical research services, real-world evidence and technology platforms (e.g., EDC, CTMS) that overlap with Certara's clinical, regulatory and real-world evidence offerings to large pharma.
  • ICON plc: ICON is a global CRO with growing technology-enabled services in biometrics, regulatory and clinical trial delivery, competing with Certara's services arm for pharma and biotech outsourcing budgets.
  • Medidata Solutions (Dassault Systèmes): Medidata provides the Rave EDC/CTMS/eCOA platform used widely in clinical trials, making it a broad incumbent adjacent to Certara's trial-related modeling and Pinnacle 21 CDISC compliance tooling.
  • Charles River Laboratories: Charles River provides preclinical CRO services and scientific software-supported workflows that overlap with Certara's preclinical modeling and consulting offerings to pharma and biotech.
  • Labcorp: Labcorp's early development and clinical trial services compete with Certara's services arm for pharma R&D outsourcing, particularly in clinical pharmacology and bioanalytical work.

Emerging players

  • L7 Informatics: L7 Informatics offers a scientific data and workflow platform for life sciences R&D, an emerging alternative to Certara's D360 scientific informatics offering.
  • ArisGlobal: ArisGlobal provides life-sciences R&D technology including pharmacovigilance and regulatory platforms, overlapping with Certara's drug safety, regulatory submission and pharmacovigilance services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights7 records

Customer concentration

Pharsight social profiles

Digital presence

Pharsight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharsight leadership team

Management profile

Number of profiles

Profiles1 record

Pharsight subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pharsight funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharsight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharsight

What does Pharsight do?

Pharsight Corporation provides software and scientific consulting services to pharmaceutical and biotechnology companies. Its portfolio centers on clinical trial simulation and pharmacokinetic/pharmacodynamic (PK/PD) analysis tools used by drug development teams to model drug behavior, optimize dosing, and support go/no-go decisions during preclinical and clinical phases. Pharsight was acquired by Certara in 2012, and its flagship Phoenix platform is now part of Certara's broader drug development software suite.

Is Pharsight a public or private company?

Pharsight is a public company. It is classified as corporate owned and is currently operating.

When was Pharsight founded?

Pharsight was founded in 1998. It employs 51 to 100 people.

Where is Pharsight based?

Pharsight is headquartered in Mountain View, United States, in the North America region.

How does Pharsight make money?

Two revenue lines are on record. Software Licenses and Subscriptions are the primary driver. The others are professional Services.

Who are Pharsight's main competitors?

Direct peers on record are Veeva Systems, Simulations Plus and Schrödinger. Broad incumbents are IQVIA, ICON plc, Medidata Solutions (Dassault Systèmes), Charles River Laboratories and Labcorp. Emerging players are L7 Informatics and ArisGlobal.

Does Pharsight have an API?

No public API is recorded for Pharsight.

What industry is Pharsight in?

Pharsight's product category is Drug Development Software. Its primary akta.pro industry code is HLAGAJAK, Pharmacovigilance & Drug Safety Software, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirePharsight Makes Strong Contribution At AAPS Annual MeetingPharsight Corporation announced its participation at the AAPS Annual Meeting in Atlanta from November 16-20, 2008, at booth #704. The company will demonstrate Phoenix WinNonlin and beta PK/PD modeling tools, and contribute three posters on model-based drug development. It also co-sponsors two AAPS Open Forums on model-based drug development.GlobeNewswireTripos to Acquire Pharsight CorporationTripos agreed to acquire Pharsight Corporation for approximately $57 million in cash, paying $5.50 per share, a 29% premium over the prior 30-day average. The deal is expected to close in Q4 2008, subject to stockholder approval and other conditions.GlobeNewswirePharsight to Present At Noble Financial Fourth Annual Equity ConferencePharsight Corporation will present at the Noble Financial Fourth Annual Equity Conference on August 18-19, 2008, in Las Vegas. CEO Shawn O'Connor and CFO Will Fredrick will discuss the company's business strategy and historical financial performance on August 19th. A live webcast and archived replay will be available on the company's website.GlobeNewswireGlobal Biotechnology Company Licenses WinNonlin AutoPilotA global biotechnology company purchased WinNonlin AutoPilot from Pharsight Corporation, becoming the seventh customer to adopt the software. The configurable tool automates clinical pharmacokinetic analysis tasks, improving productivity and report quality. The customer already uses Pharsight's PKS for data management.GlobeNewswirePharsight Announces Fiscal First Quarter 2009 Earnings Release Date and Conference CallPharsight Corporation announced it will release fiscal Q1 2009 results after market close on July 24, 2008, and host a conference call on July 25. The call will be webcast and available for replay, with dial-in numbers provided.GlobeNewswirePharsight Added to Russell Microcap IndexPharsight Corporation was added to the Russell Microcap Index when Russell Investments reconstituted its indexes on June 27, 2008. Membership remains for one year and includes automatic inclusion in growth and value style indexes. The company expects the inclusion to generate greater investor interest.GlobeNewswireKnobias, Inc. Announces Pharsight Corporation as the SPOT of the Week in Its Small-Cap ClipReportKnobias, Inc. selected Pharsight Corporation as the SPOT of the week in its Small-Cap ClipReport. Pharsight reported FY05 revenues of $22.6M, up 153% since 2000, and two consecutive years of 25% revenue growth. The company faces potential dilution from convertible preferred stock held by PIPE investors.GlobeNewswireStreetFusion to Feature Live and On-Demand Webcasts of Quarterly Earnings Conference Calls for Peak International Limited, Pharsight Corporation, PolyMedica Corporation, Pinnacle Entertainment, Inc.;StreetFusion will webcast quarterly earnings calls for Peak International, Pharsight, PolyMedica, and Pinnacle Entertainment on July 24, 2001. The live and on-demand webcasts are free, with dates and times subject to change.GlobeNewswireStreetFusion To Feature Live and On-Demand Webcasts of Quarterly Earnings Conference Calls for Osteotech Incorporated, Oshkosh Truck Corporation, Pinnacle Systems Incorporated, Pharsight CorporationStreetFusion will webcast quarterly earnings calls for Osteotech, Oshkosh Truck, Pinnacle Systems, and Pharsight on April 26, 2001. The live and on-demand webcasts are free, with archived versions available on the StreetFusion website.GlobeNewswireStreetFusion to Feature Live and On-Demand Earnings Conference Call Webcast for Pharsight CorporationPharsight Corporation will webcast its quarterly earnings conference call live on StreetFusion on April 26, 2001, at 4:30 PM Eastern Time. An on-demand webcast will be available until May 7, 2001, on both StreetFusion and Pharsight's website.